Quick Takeaways
- Vestal Point Capital, LP filed SCHEDULE 13G for Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN).
- Disclosed ownership: 6.5%.
- Date of event: 31 Dec 2025.
Vestal Point Capital, LP - 31 Dec 2025 SCHEDULE 13G Report for Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN)
- Filing Manager
- Vestal Point Capital, LP
- Reporting Manager
- Vestal Point Capital, LP
- Symbol
- ELVN
- Shares outstanding
- 58,923,077 shares
- Disclosed Ownership
- 3,830,000 shares
- Ownership
- 6.5%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 16:07:16 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vestal Point Capital, LP disclosed 6.5% ownership in Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:07.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 6.5% | 3,830,000 | 0 | 3,830,000 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 6.5% | 3,830,000 | 0 | 3,830,000 | /s/ Ryan Wilder | Ryan Wilder, Individually |